Company expects to have a Data Safety and Monitoring Board (DSMB) review by the end of this year  Newton, Massachusetts, May 31, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced completion of enrollment of the

 READ MORE

ABC008 potently and selectively depletes highly cytotoxic T cells which attack and destroy muscle tissue in IBM without affecting protective T cell populations  Newton, Massachusetts, April 3, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today

 READ MORE

T-LGLL is an autoimmune disorder characterized by cytotoxic T lymphocytes which attack neutrophils and red blood cell precursors Newton, Massachusetts, October 4, 2022 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced initiation of a Phase

 READ MORE

 Industry veteran brings extensive experience in building and leading biopharmaceutical companies Newton, Massachusetts, October 3, 2022 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Alex Martin as Chief Executive Officer. He brings to

 READ MORE

Newton, Massachusetts, June 23, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that Dietmar Berger, M.D., Ph.D., currently the Chief Medical Officer and Head of Global Development at Sanofi will contribute his considerable experience to the company’s Board of

 READ MORE

Industry veteran brings extensive clinical development experience in immunology, immuno-oncology, and rare diseases to  leadership team Newton, Massachusetts, June 21, 2022– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of H. Jeffrey Wilkins, M.D.,

 READ MORE

Newton, Massachusetts, June 7, 2022, Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the presentation of additional clinical results from its ongoing Phase 1 clinical trial of its lead product candidate ABC008 in patients with inclusion

 READ MORE

ABC008 is a first-in-class monoclonal antibody designed to selectively deplete highly cytotoxic T cells ABC008 offers therapeutic potential across a broad range of diseases in addition to inclusion body myositis, such as T cell large granular lymphocytic leukemia (T-LGLL) and mature T cell malignancies Newton, Massachusetts, November 5, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing

 READ MORE

Newton, Massachusetts, October 19, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company’s Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience

 READ MORE

Newton, MA, October 6, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that a Trial in Progress poster describing a Phase 1 trial of ABC008 will be presented at the Lymphoma, Leukemia and Myeloma Congress Conference being held

 READ MORE

Study sponsored by ImaginAb supports hypothesis that CD8+ T cells are present throughout the skeletal muscle system in inclusion body myositis  Proprietary ImmunoPET technology developed by ImaginAb provides a more comprehensive view of T cell infiltration than offered by muscle biopsies Newton, MA, June 30, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for

 READ MORE

Financing round led by Mass General Brigham Ventures and Sanofi Ventures Proceeds to support advancement of the lead autoimmune program into clinical development, as well as further development of the company’s pipeline  Newton, MA, January 7, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic

 READ MORE

Inclusion body myositis (IBM)is an autoimmune condition in which cytotoxic T cells chronically attack muscle cells, leading to progressive weakness and severe disability Abcuro’s lead program, ABC008, is an anti-KLRG1 antibody capable of depleting highly differentiated cytotoxic T cells that are pathogenic in IBM Newton, MA, June 9, 2020 – Abcuro, Inc., a clinical-stage biotechnology

 READ MORE